Barriers to COVID-19 Vaccine Uptake in the LGBTQIA Community Barriers to COVID-19 Vaccine Uptake in the LGBTQIA Community
This study aimed to determine factors that contribute to vaccine hesitancy and barriers to vaccine uptake that are unique to LGBTQIA individuals.American Journal of Public Health (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 12, 2022 Category: Infectious Diseases Tags: Public Health & Prevention Journal Article Source Type: news
Improv Theater Takes a Shot at Proving Vaccine Knowledge Improv Theater Takes a Shot at Proving Vaccine Knowledge
One theater is partnering with health officials to advocate for the COVID-19 vaccine with a healthy dose of humor.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 8, 2022 Category: Infectious Diseases Tags: Family Medicine/Primary Care News Source Type: news
Clinton's NIH Support Sparked 'Golden Age' of Biomedical Research, Scientists Say
A panel including Dr. Anthony Fauci recalled the Clinton era as a turning point in vaccine development and the fight against HIV/AIDS. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - March 30, 2022 Category: American Health Source Type: news
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
TITUSVILLE, N.J., March 29, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.1,2 Co-developed as part of a collaboration with ViiV Healthcare, CABENUVA is the first ...
Source: Johnson and Johnson - March 30, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
‘Africa must be self-sufficient’: John Nkengasong on learning the deadly lessons of pandemics
The outgoing director of Africa Centres for Disease Control has seen Ebola, Aids and now Covid – and warns complacency is dangerousThe past five years have been “like going from one fire to the next, with barely any time to catch your breath”, says John Nkengasong, the outgoing head of the body charged with responding to health emergencies in Africa.A relentless term as the first director of the Africa Centres for Disease Control and Prevention (Africa CDC) saw Nkengasong manage the response to Ebola and Lassa fever outbreaks. But nothing compared to the formidable test brought by Covid-19.Continue reading... (Source...
Source: Guardian Unlimited Science - March 28, 2022 Category: Science Authors: Emmanuel Akinwotu Tags: Global development Global health Africa Coronavirus Infectious diseases World news Science Microbiology Aids and HIV Vaccines and immunisation Ebola Inequality Source Type: news
Impaired Response to COVID-19 Vaccination in Advanced HIV Impaired Response to COVID-19 Vaccination in Advanced HIV
These results bring into question the efficacy of two doses of COVID-19 vaccines among people with advanced HIV infection.AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 17, 2022 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
To End COVID-19, We Have to Admit That We ’ve Failed
In 1985, the first HIV vaccine trial was launched with great fanfare. The previous year, Margaret Heckler, the U.S. Secretary of Health and Human Services, confidently declared that an HIV vaccine would be created within two years. But almost four decades after the initial discovery of the HIV virus, there is still no viable HIV/AIDS vaccine. That doesn’t mean, though, that there is no cure. The grueling and largely thankless work of trialing an HIV/AIDS vaccine has continued steadily over the past four decades (the most recent one launched in January 2022, using Moderna’s mRNA technology), making it the longes...
Source: TIME: Health - March 16, 2022 Category: Consumer Health News Authors: Dan Werb Tags: Uncategorized COVID-19 Source Type: news
Bharat Biotech enters into partnership with Biofabri for TB vaccine
The new TB vaccine, 'MTBVAC', is being manufactured and developed by Biofabri, in close collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 16, 2022 Category: Pharmaceuticals Source Type: news
SARS-CoV-2 infection may lead to small-airways disease
in the long term, whic...Read more on AuntMinnie.comRelated Reading:
CT proves its diagnostic value during COVID-19 pandemic
ECR: How can imaging screen for COVID damage to kidneys?
AI mines CT, lab results to predict COVID-19 severity
Breakthrough COVID-19 infection milder in vaccinated patients
AI reconstruction aids lung nodule detection on ultralow-dose CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2022 Category: Radiology Source Type: news
HHS: Vaccines Federal Implementation Plan, Request for Comments; Correction
Notice from the Department of Health and Human Services' Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health making corrections to theMarch 2, 2022 notice regarding theVaccines Federal Implementation Plan. The earlier notice contained an incorrect title and did not provide a link to the plan. Comments on the plan are due by March 29, 2022. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - March 9, 2022 Category: Rural Health Source Type: news
SARS-CoV-2 Vaccine Immunogenicity in Older People With HIV SARS-CoV-2 Vaccine Immunogenicity in Older People With HIV
A new study provides insight into SARS-CoV-2 immunogenicity after COVID-19 vaccination in people living with HIV.HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 3, 2022 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
HHS: Meeting of the Vaccines Federal Implementation Plan
The Department of Health and Human Services' Office of
Infectious Disease and HIV/AIDS Policy, Office of the
Assistant Secretary for Health has released the draft
Vaccines Federal Implementation Plan 2021-2025 for public comment. The Vaccines Federal Implementation Plan includes information on the federal agency immunization activities that
advance the goals of the Vaccines National Strategic Plan 2021-2025. The target audience is federal agencies and external partners who work in the area of vaccination. It does not outline mandates or other COVID-19 response measures. Comments on the plan are due by March 29, 2022. (...
Source: Federal Register updates via the Rural Assistance Center - March 2, 2022 Category: Rural Health Source Type: news
Malawi: Covid-19 Vaccine Uptake Triples Among Vulnerable Groups in Lilongwe
[Nyasa Times] Vaccination against Covid-19 has reportedly tripled among persons with disabilities (PWDs) and people living with HIV and Aids (PLHIV) under Traditional Authorities (T/As) in Chiseka and Kalolo in Lilongwe. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 25, 2022 Category: African Health Source Type: news
Knowing the Origins of COVID-19 Won ’t Change Much
Over two years since the first cases started appearing in Wuhan, China, there is much we don’t know about the origins of SARS-CoV-2, the virus causing COVID-19. But a quick resolution to that question is possible: scientists could find bats in a cave somewhere in China or in southeast Asia and trace a chain leading from those bats to the COVID-19 outbreak in Wuhan. Realistically, however, recent history offers little promise for this to happen quickly. For example, about 14 years elapsed between the identification of HIV as the virus that caused AIDS and a demonstration of its modern transition to humans from a speci...
Source: TIME: Health - February 23, 2022 Category: Consumer Health News Authors: Robert C. Gallo and Dean T. Jamison Tags: Uncategorized COVID-19 Source Type: news
Adult Vaccines 2022: Who Needs What, and When? Adult Vaccines 2022: Who Needs What, and When?
Dr Sandra Fryhofer hits the highlights of the 2022 adult immunization schedule, just released by ACIP.Medscape Internal Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 17, 2022 Category: Infectious Diseases Tags: Internal Medicine Commentary Source Type: news
